Metastatic Breast Cancer Patients - New Study

Genentech and 23andMe, a genetic testing company, haverecently partnered to launch a new breast cancer research initiative. Genetics can sometimes explain why people differ in how well they respond to a drug and/or experience side effects. One of the goals of this web-based study is to determine if a person’s genes could play a role in how they respond to bevacizumab (also known as Avastin^®). The study is enrolling 1,000 individuals whohave received bevacizumab (also known as Avastin^®) for metastatic breast cancer on or before 2011.

Participation is free, but you must have access to a computer and the Internet. Participants in the study will submit DNA samples via an at-home saliva collection kit and potentially a blood sample through a qualified laboratory.  You willcreate an online account to take surveys about your experience with Avastin and to receive updates on research progress. You also have the option to join the 23andMe service (for free) to learn more about genetics and your health andancestry.

For more information about this study, and to sign up, visit https://www.23andme.com/invite-study/

Questions? Email invite-study@23andme.com.